(BIB) ProShares Ultra Nasdaq - Overview
Etf: Leveraged, Biotech, ETF
Dividends
| Dividend Yield | 1.10% |
| Yield on Cost 5y | 0.57% |
| Yield CAGR 5y | 213.80% |
| Payout Consistency | 22.0% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 41.1% |
| Relative Tail Risk | 3.04% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.09 |
| Alpha | 29.99 |
| Character TTM | |
|---|---|
| Beta | 1.396 |
| Beta Downside | 1.162 |
| Drawdowns 3y | |
|---|---|
| Max DD | 45.31% |
| CAGR/Max DD | 0.35 |
Description: BIB ProShares Ultra Nasdaq December 22, 2025
The ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) is a leveraged ETF that seeks to deliver twice the daily performance of a Nasdaq-based biotechnology and pharmaceutical index. It typically allocates at least 80% of its assets to the index constituents or equivalent instruments, and it is classified as a non-diversified, leveraged equity fund.
Key sector drivers include FDA approval cycles, which can cause sharp price moves in biotech stocks, and the broader R&D spending trends-U.S. biotech R&D expenditure grew ~7% YoY in Q3 2024, supporting pipeline growth. Recent KPI data shows the underlying index’s average forward-looking earnings growth of ~15% and a median market-cap of roughly $4 billion, indicating a tilt toward mid-cap innovators.
For a deeper quantitative assessment, you might explore ValueRay’s analytics to see how BIB’s leverage profile behaves across volatility regimes.
What is the price of BIB shares?
Over the past week, the price has changed by +4.26%, over one month by +6.49%, over three months by +23.56% and over the past year by +53.81%.
Is BIB a buy, sell or hold?
What are the forecasts/targets for the BIB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 100.7 | 16.2% |
BIB Fundamental Data Overview February 05, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 90.0m USD (90.0m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 90.0m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 90.0m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 11.06% (E(90.0m)/V(90.0m) * Re(11.06%) + (debt-free company))
Discount Rate = 11.06% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)